Tigermed Pays $50 Million to Acquire Frontage Labs, a US/China CRO

Hangzhou Tigermed Consulting, a China clinical-stage CRO, will add pre-clinical capability to its service offerings by acquiring Frontage Labs, headquartered in Pennsylvania, for $50.2 million. Frontage Labs provides both pre-clinical and clinical CRO services through its facilities in Pennsylvania and the Zhangjiang Hi-Tech Park in Shanghai. Tigermed said Frontage would continue to operate independently, with its current management team, led by CEO Dr. Song Li, remaining intact. More details.... Stock Symbol: (SHE: 300347) Share this with colleagues: // //